Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Gc Cell Corp. (144510.KQ)
KRW13,580.00
+570.00 (+4.38%)
KR KOE Healthcare Biotechnology
Address
107, Ihyeon-ro 16924
Yongin-si, KR
Yongin-si, KR
CEO
Jin-Hyung Park
Website
gccell.com
IPO
2016-06-23
ISIN KR7144510005
Description
GC Cell Corp. engages in the research and development of cell curing agents and in the transport and sale of consignment inspection samples. It offers cell therapy products, cell banking, clinical laboratory services, clinical trials, and bio logistics. The company was founded on June 21, 2011, and is headquartered in Yongin-si, South Korea.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
KRW13,580.00
+570.00 (+4.38%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
46.1K
Beta
1.51
Float Shares
7.88M
Free Float %
52.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.21% | -11.25% | -17.98% | -23.00% | -25.93% | -21.61% | -7.24% | -57.19% | -80.40% | -59.50% | -59.50% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
13,580.00
DCF (Levered)
2,197.04
-83.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
2.21
Grey zone
Piotroski F-Score
3 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-5.1% Q1'26: -5.5% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-249.9% Q1'26: +84.3% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-2.7% Q1'26: -46.4% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-8.3% Q1'26: -13.7% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-5.1% ★ Q1'26: -7.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+0.1% ★ Q1'26: +5.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×47.71× Q1'26: -18.32× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
39.30B
est.
|
44.50B
est.
|
57.90B
est: 48.60B (+19.1%)
|
85.56B
est: 52.10B (+64.2%)
|
168.31B
est: 56.20B (+199.5%)
|
236.12B
est: 236.00B (+0.1%)
|
187.54B
est: 183.30B (+2.3%)
|
174.45B
est: 193.30B (-9.8%)
|
165.52B
est: 176.30B (-6.1%)
|
| EBITDA |
2.65B
est.
|
3.00B
est.
|
984.55M
est: 3.28B (-70.0%)
|
10.55B
est: 3.52B (+199.8%)
|
43.80B
est: 3.79B (+1,054.4%)
|
52.61B
est: 15.93B (+230.2%)
|
11.58B
est: 12.38B (-6.4%)
|
-57.66B
est: 8.68B (-764.4%)
|
1.68B
est: 7.91B (-78.8%)
|
| EBIT |
92.84M
est.
|
105.12M
est.
|
-3.13B
est: 114.81M (-2,825.2%)
|
6.36B
est: 123.07M (+5,071.1%)
|
36.41B
est: 132.76M (+27,323.3%)
|
38.99B
est: 557.49M (+6,893.7%)
|
-4.06B
est: 433.00M (-1,036.5%)
|
-73.69B
est: -5.64B (-1,206.3%)
|
-13.79B
est: -5.14B (-168.1%)
|
| Net Income |
3.02B
est.
|
3.35B
est.
|
-2.28B
est: 1.62B (-240.2%)
|
4.16B
est: 2.16B (+92.2%)
|
31.42B
est: 2.25B (+1,293.5%)
|
24.99B
est: 39.18B (-36.2%)
|
-174.01M
est: 14.10B (-101.2%)
|
-73.90B
est: 17.84B (-514.3%)
|
-258.94B
|
| SGA |
1.36B
est.
|
1.54B
est.
|
2.35B
est: 1.69B (+39.6%)
|
696.95M
est: 1.81B (-61.5%)
|
5.52B
est: 1.95B (+183.0%)
|
7.91B
est: 8.19B (-3.4%)
|
9.76B
est: 6.36B (+53.4%)
|
8.21B
est: 8.35B (-1.7%)
|
8.36B
est: 7.61B (+9.8%)
|
| EPS |
201.00
est.
|
223.00
est.
|
-216.00
est: 108.00 (-300.0%)
|
394.00
est: 144.00 (+173.6%)
|
2,785.00
est: 150.00 (+1,756.7%)
|
1,664.00
est: 2,606.00 (-36.1%)
|
-12.00
est: 938.00 (-101.3%)
|
-4,915.82
est: 1,185.00 (-514.8%)
|
-17,202.54
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-26 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-07 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-06 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-04 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
1.69B
OE per share TTM
110.77
Owner's Yield
0.55%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
56.4%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 26 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Samsung Kodex Fn Growth ETF 325010.KS | 0.00% | 4.4K | 0.30% |
| 2 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 352.3K | 0.06% |
| 3 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.00% | 7.6K | 0.56% |
| 4 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 143.1K | 0.39% |
| 5 | Vanguard FTSE Developed Asia Pacific All Cap Index ETF VA.TO | 0.00% | 2.6K | 0.22% |
| 6 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 87.3K | 0.29% |
| 7 | Vanguard FTSE Developed All Cap ex North America Index ETF (CAD-hedged) VI.TO | 0.00% | 5.9K | 0.22% |
| 8 | Vanguard FTSE Developed All Cap ex North America Index ETF VIU.TO | 0.00% | 68.0K | 0.23% |
| 9 | Vanguard FTSE Pacific ETF VPL | 0.00% | 115.7K | 0.07% |
| 10 | Vanguard FTSE Developed All Cap ex U.S. Index ETF VDU.TO | 0.00% | 2.2K | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-17.11M
Shares Outstanding
15.03M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jai-Wang Kim | CEO & Chairman | — | male |
| Won Sung-Yong | Chief Executive Officer | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 144510.KQ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
